A report in BMC Neurology (July) describes how three people with ME/CFS (one of whom had Hodgkin's disease) experienced a significant degree of improvement during and after the use of two drugs – rituximab and methotrexate –that depress what is called B cell function.
The authors of this paper suggest that there could be a sub-group of people with ME/CFS where immunomodulatory drugs that modify B cell numbers and function could be an effective form of treatment.
No comments:
Post a Comment